Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis
Open accessAbstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron degeneration with limited treatment options. In this study, we investigated the pathological role of microRNA-485-3p (miR-485-3p) in ALS, particularly its regulation of PGC-1α, a transcriptional coactivator essential for mitochondrial function and neuroprotection. We also evaluated the therapeutic potential of BMD-001S, a nanoparticle-based formulation encapsulating an antisense oligonucleotide targeting miR-485-3p. Our results demonstrated that miR-485-3p expression was significantly elevated in both SOD1G93A-expressing HMC3 microglial cells and in the spinal cords of SOD1G93A transgenic mice at late disease stages, implicating its contribution to ALS pathogenesis. Intravenous administration of BMD-001S effectively reduced miR-485-3p levels and restored PGC-1α mRNA and PGC-1α protein expression in the spinal cord. These molecular changes were associated with notable therapeutic outcomes, including reduced SOD1 protein aggregation, decreased neuroinflammation, and lower neurofilament light chain concentrations in cerebrospinal fluid. Moreover, BMD-001S treatment was associated with improvements in electrophysiological parameters and preservation of neuromuscular junction integrity during the observation period in SOD1G93A transgenic mice. Taken together, these findings suggest that miR-485-3p/PGC-1α pathway is a promising therapeutic target in ALS and support the potential of BMD-001S as a novel treatment strategy for the disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433 · see citing works
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143 · see citing works
Many roads to maturity: microRNA biogenesis pathways and their regulation
Winter, J. J., Jung, S., Keller, S., Gregory, R. I., & Diederichs, S. (2009) · Nature Cell Biology · doi:10.1038/ncb0309-228 · Cited by 2,646 · see citing works
Brown, R. H., & Al‐Chalabi, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1603471 · Cited by 2,473 · see citing works
Rowland, L. P., & Shneider, N. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442207 · Cited by 1,851 · see citing works
Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Miller, T. M., Cudkowicz, M. E., Genge, A., Shaw, P. J., Sobue, G., Bucelli, R. C., Chiò, A., Van Damme, P., Ludolph, A. C., Glass, J. D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204705 · Cited by 966 · see citing works
Xuan, L., Ju, Z., Skonieczna, M., Zhou, P., & Huang, R. (2023) · MedComm · doi:10.1002/mco2.327 · Cited by 865 · see citing works
Biocompatibility of engineered nanoparticles for drug delivery
Naahidi, S., Jafari, M., Edalat, F., Raymond, K. P., Khademhosseini, A., & Chen, P. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.12.013 · Cited by 814 · see citing works
MicroRNA-206 Delays ALS Progression and Promotes Regeneration of Neuromuscular Synapses in Mice
Williams, A. H., Valdez, G., Moresi, V., Qi, X., McAnally, J., Elliott, J. L., Bassel‐Duby, R., Sanes, J. R., & Olson, E. N. (2009) · Science · doi:10.1126/science.1181046 · Cited by 738 · see citing works
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003715 · Cited by 565 · cited 4× · see citing works
“Therefore, the clearance of SOD1 aggregates and reduction in neuroinflammation are considered critical strategies for prolonging survival and alleviating symptoms in ALS [10,43,44].”
InfluentialNeurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
Lu, C.-H., Macdonald-Wallis, C., Gray, E., Pearce, N., Petzold, A., Norgren, N., Giovannoni, G., Fratta, P., Sidle, K., Fish, M., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001642 · Cited by 563 · see citing works
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H. T. T., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 554 · see citing works
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs
Jaiswal, M. K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21528 · Cited by 456 · see citing works
Butovsky, O., Jedrychowski, M. P., Cialic, R., Krasemann, S., Murugaiyan, G., Fanek, Z., Greco, D. J., Wu, P. M., Doykan, C. E., Kiner, O., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24304 · Cited by 358 · see citing works
Guidelines for preclinical animal research in ALS/MND: A consensus meeting
Ludolph, A. C., Bendotti, C., Blaugrund, E., Chiò, A., Greensmith, L., Loeffler, J., Mead, R. J., Niessen, H. G., Petri, S., Pradat, P., et al. (2010) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482960903545334 · Cited by 315 · see citing works
Chapman, J. R., & Waldenström, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141853 · Cited by 315 · see citing works
The toxicity of nanoparticles and their interaction with cells: an in vitro metabolomic perspective
Awashra, M., & Młynarz, P. (2023) · Nanoscale Advances · doi:10.1039/d2na00534d · Cited by 315 · see citing works
Anderson, R. M., Barger, J. L., Edwards, M. G., Braun, K. H., O’Connor, C. E., Prolla, T. A., & Weindruch, R. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2007.00357.x · Cited by 283 · cited 1× · see citing works
“In addition, PGC-1 α protein stability and turnover can be regulated by proteasomal degradation pathways, and baseline molecular heterogeneity across spinal cord segments may further contribute to discordance between transcript and protein levels [70,71].”
Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice
Koval, E. D., Shaner, C., Zhang, P., du Maine, X., Fischer, K., Tay, J., Chau, B. N., Wu, G. F., & Miller, T. M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt261 · Cited by 236 · see citing works
Emde, A., Eitan, C., Liou, L., Libby, R. T., Rivkin, N., Magen, I., Reichenstein, I., Oppenheim, H., Eilam, R., Silvestroni, A., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490493 · Cited by 215 · see citing works
Bonafede, R., & Mariotti, R. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00080 · Cited by 205 · see citing works
Vinsant, S. L., Mansfield, C., Jiménez-Moreno, R., Moore, V. D. G., Yoshikawa, M., Hampton, T., Prevette, D. M., Caress, J. B., Oppenheim, R. W., & Milligan, C. (2013) · Brain and Behavior · doi:10.1002/brb3.142 · Cited by 175 · see citing works
Integrated expression profiles of mRNA and miRNA in polarized primary murine microglia
Freilich, R. W., Woodbury, M. E., & Ikezu, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079416 · Cited by 160 · see citing works
Reduced changes in protein compared to mRNA levels across non-proliferating tissues
Perl, K., Ushakov, K., Pozniak, Y., Barnea, O. Y., Bhonker, Y., Shivatzki, S., Geiger, T., Avraham, K. B., & Ron Shamir, A. (2017) · BMC Genomics · doi:10.1186/s12864-017-3683-9 · Cited by 156 · see citing works
Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Verde, F., Otto, M., & Silani, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.679199 · Cited by 152 · see citing works
MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1α expression
Lou, C., Xiao, M., Cheng, S., Lu, X., Jia, S., Ren, Y., & Li, Z. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.27 · Cited by 151 · see citing works
Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis
Andrews, J. A., Jackson, C. E., Heiman-Patterson, T. D., Bettica, P. U., Brooks, B. R., & Pioro, E. P. (2020) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2020.1771734 · Cited by 150 · see citing works
Bruneteau, G., Simonet, T., Bauché, S., Mandjee, N., Malfatti, E., Girard, E., Tanguy, M., Béhin, A., Khiami, F., Sariali, E., et al. (2013) · Brain · doi:10.1093/brain/awt164 · Cited by 137 · see citing works
Pun, S., Sigrist, M., Santos, A. F., Rüegg, M. A., Sanes, J. R., Jessell, T. M., Arber, S., & Caroni, P. (2002) · Neuron · doi:10.1016/s0896-6273(02)00670-0 · Cited by 118 · see citing works
Structural basis of lipid biosynthesis regulation in Gram‐positive bacteria
Schujman, G. E., Guerin, M. E., Buschiazzo, A., Schaeffer, F., Llarrull, L. I., Reh, G., Vila, A. J., Alzari, P. M., & de Mendoza, D. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601284 · Cited by 116 · see citing works
The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis
Zhao, J., Wang, X., Huo, Z., Chen, Y., Liu, J., Zhao, Z., Meng, F., Su, Q., Bao, W., Zhang, L., et al. (2022) · Cells · doi:10.3390/cells11132049 · Cited by 115 · see citing works
Emerging Roles of miRNAs in Brain Development and Perinatal Brain Injury
Cho, K. H. T., Xu, B., Blenkiron, C., & Fraser, M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00227 · Cited by 114 · see citing works
Modelling the Effects of Penetrance and Family Size on Rates of Sporadic and Familial Disease
Al‐Chalabi, A., & Lewis, C. M. (2011) · Human Heredity · doi:10.1159/000330167 · Cited by 112 · see citing works
Vinsant, S. L., Mansfield, C., Jiménez-Moreno, R., Moore, V. D. G., Yoshikawa, M., Hampton, T., Prevette, D. M., Caress, J. B., Oppenheim, R. W., & Milligan, C. (2013) · Brain and Behavior · doi:10.1002/brb3.143 · Cited by 107 · see citing works
Yang, L., Ma, F., Liu, F., Chen, J., Zhao, X., & Xu, Q. (2020) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2020.01.018 · Cited by 103 · see citing works
Thau, N., Knippenberg, S., Körner, S., Rath, K. J., Dengler, R., & Petri, S. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318275df4b · Cited by 98 · see citing works
Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis
Raheja, R., Regev, K., Healy, B. C., Mazzola, M. A., Beynon, V., von Glehn, F., Paul, A., Diaz‐Cruz, C., Gholipour, T., Glanz, B. I., et al. (2018) · Muscle & Nerve · doi:10.1002/mus.26106 · Cited by 97 · see citing works
PGC-1 is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis
Eschbach, J., Schwalenstöcker, B., Soyal, S. M., Bayer, H., Wiesner, D., Akimoto, C., Nilsson, A.-C., Birve, A., Meyer, T., Dupuis, L., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt202 · Cited by 79 · see citing works
Huang, M., Liu, Y., Yao, X., Qin, D., & Su, H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00416-x · Cited by 68 · see citing works
MicroRNA in Brain pathology: Neurodegeneration the Other Side of the Brain Cancer
Godlewski, J. A., Lenart, J., & Salińska, E. (2019) · Non-Coding RNA · doi:10.3390/ncrna5010020 · Cited by 67 · see citing works
Dobrowolny, G., Martone, J., Lepore, E., Casola, I., Petrucci, A., Inghilleri, M., Morlando, M., Colantoni, A., Scicchitano, B. M., Calvo, A., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-020-00397-6 · Cited by 65 · see citing works
Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment
Vucic, S., Ferguson, T. A., Cummings, C., Hotchkin, M. T., Genge, A. L., Glanzman, R., Roet, K. C. D., Cudkowicz, M., & Kiernan, M. C. (2021) · Muscle & Nerve · doi:10.1002/mus.27392 · Cited by 62 · see citing works
Takeuchi, R., Tada, M., Shiga, A., Toyoshima, Y., Konno, T., Sato, T., Nozaki, H., Kato, T., Horie, M., Shimizu, H., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0335-2 · Cited by 61 · see citing works
NfL makes regulatory debut as neurodegenerative disease biomarker
Mullard, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/d41573-023-00083-z · Cited by 55 · see citing works
Park, H. R., & Yang, E. J. (2021) · Diagnostics · doi:10.3390/diagnostics11091546 · Cited by 51 · see citing works
Benatar, M. G., Ostrow, L. W., Lewcock, J. W., Bennett, F., Shefner, J. M., Bowser, R. P., Larkin, P., Bruijn, L. I., & Wuu, J. (2023) · Annals of Neurology · doi:10.1002/ana.26860 · Cited by 48 · see citing works
Ryu, I. S., Kim, D. H., Ro, J.-Y., Park, B., Kim, S. H., Im, J.-Y., Lee, J., Yoon, S. J., Kang, H., Iwatsubo, T., et al. (2023) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2023.110603 · Cited by 42 · see citing works
Self-citationSchipper, L. J., Raaphorst, J., Aronica, E., Baas, F., de Haan, R. J., de Visser, M., & Troost, D. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12284 · Cited by 41 · see citing works
Species-Specific miRNAs in Human Brain Development and Disease
Prodromidou, K., & Matsas, R. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00559 · Cited by 37 · see citing works
Byrnes, A. E., Domínguez, S. L., Yen, C., Laufer, B. I., Foreman, O., Reichelt, M., Lin, H., Sagolla, M. S., Hötzel, K., Ngu, H., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.005 · Cited by 35 · see citing works
Morpholino-mediated SOD1 reduction ameliorates an amyotrophic lateral sclerosis disease phenotype
Nizzardo, M., Simoné, C., Rizzo, F., Ulzi, G., Ramirez, A., Rizzuti, M., Bordoni, A., Bucchia, M., Gatti, S., Bresolin, N., et al. (2016) · Scientific Reports · doi:10.1038/srep21301 · Cited by 33 · see citing works
Review of flow cytometry as a tool for cell and gene therapy
Lazarski, C. A., & Hanley, P. J. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.10.005 · Cited by 25 · see citing works
The role of microRNA-485 in neurodegenerative diseases
Ryu, I. S., Kim, D. H., Cho, H., & Ryu, J. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0039 · Cited by 24 · see citing works
Self-citationSala, G., Arosio, A., Conti, E., Beretta, S., Lunetta, C., Riva, N., Ferrarese, C., & Tremolizzo, L. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.3.438 · Cited by 23 · see citing works
Woo, T., Yoon, M.-H., Kang, S., Park, S., Cho, J.-H., Hwang, Y. J., Ahn, J., Jang, H., Shin, Y.-J., Jung, E., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02862-z · Cited by 23 · see citing works
Nanomedicine and neurodegenerative disorders: so close yet so far
Tosi, G., Vandelli, M. A., Forni, F., & Ruozi, B. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1041374 · Cited by 22 · see citing works
Neel, D. V., Basu, H., Gunner, G., & Chiu, I. M. (2022) · Immunological Reviews · doi:10.1111/imr.13083 · Cited by 22 · see citing works
Lim, Y. N., Ryu, I. S., Jung, Y., Helmlinger, G., Kim, I., Park, H. W., Kang, H., Lee, J., Lee, H. J., Lee, K. S., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102340 · Cited by 17 · see citing works
Self-citationProfiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis
Santos, M. O., & de Carvalho, M. A. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2355983 · Cited by 16 · see citing works
Putative roles of SLC7A5 (LAT1) transporter in pain
Alles, S. R. A., Gómez, K., Moutal, A., & Khanna, R. (2020) · Neurobiology of Pain · doi:10.1016/j.ynpai.2020.100050 · Cited by 15 · see citing works
Rafe, M. R. (2023) · Nanotheranostics · doi:10.7150/ntno.88849 · Cited by 15 · see citing works
Bastone, A., Fumagalli, E. R., Bigini, P., Perini, P., Bernardinello, D., Cagnotto, A., Mereghetti, I., Curti, D., Salmona, M., & Mennini, T. (2009) · Journal of Proteome Research · doi:10.1021/pr900569d · Cited by 14 · see citing works
Takahashi, R. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.001 · Cited by 13 · see citing works
Recent Advances in the Roles of MicroRNA and MicroRNA-Based Diagnosis in Neurodegenerative Diseases
Zhang, J., Chen, Z., Chen, H., Deng, Y., Li, S., & Jin, L. J. (2022) · Biosensors · doi:10.3390/bios12121074 · Cited by 13 · see citing works
Triggs, W. J., Brown, R. H., & Menkes, D. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmcpc069009 · Cited by 9 · see citing works
Akashi, T., Noguchi, S., Takahashi, Y., Nishimura, T., & Tomi, M. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.12.028 · Cited by 8 · see citing works
Sojdeh, S., Safarkhani, M., Daneshgar, H., Aldhaher, A., Heidari, G., Zare, E. N., Iravani, S., Zarrabi, A., & Rabiee, N. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117080 · Cited by 8 · see citing works
miRNA-214 to predict progression and survival in ALS
Noh, M., Kwon, M., Oh, K., Nahm, M., Park, J., Jin, H. K., Bae, J., Son, B., & Kim, S. H. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-335177 · Cited by 7 · see citing works
Self-citationMagrì, B., D’Amico, A. G., Maugeri, G., Morello, G., Cognata, V. L., Saccone, S., Federico, C., Cavallaro, S., & D’Agata, V. (2023) · Neuropeptides · doi:10.1016/j.npep.2023.102386 · Cited by 3 · see citing works
Koh, H. S., Lee, S., Lee, H. J., Min, J.-W., Iwatsubo, T., Teunissen, C. E., Cho, H., & Ryu, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073566 · Cited by 2 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 7
- Miller, 2012, Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND), Cochrane Database Syst. Rev., 2012, CD001447
- Guarner, 1994, Problems in counting CD4+ T-cells, Rev. Investig. Clin., 46, 163
- Rose, 2000, Selective attention, ideal observer theory and ‘early’ visual channels, Spat. Vis., 14, 77
- Cen, 2013, Association between urinary cadmium and clinicopathological characteristics of breast cancer, Zhonghua Zhong Liu Za Zhi, 35, 632
- Pollari, 2018, In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration, J. Vis. Exp., 136, 57741
- Liu, 2008, A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse, J. Vis. Exp., 21, 960
- Tse, 2014, The neuromuscular junction: Measuring synapse size, fragmentation and changes in synaptic protein density using confocal fluorescence microscopy, J. Vis. Exp., 94, 52220
Cited by
Sorted by citations
You, Y., Duan, D., & Xiang, Q. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06029-x · Cited by 2 · see citing works
Ata, N., Mytych, J. S., Cerghet, M., Rattan, R., Govil, S., Giri, S., & Mao‐Draayer, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114935 · Cited by 1 · see citing works
- Authors
- Ryu, I. S., Ha, D.-I., Jung, Y.-J., Lee, H. J., Kim, I., Lim, Y. N., Min, H. S., Kim, S. H., Yoon, I., Cho, H.-J., & Ryu, J.-H.
- Affiliations
- BIORCHESTRA Co., Ltd., 1, Gukjegwahak 2-ro, Yuseong-gu, Daejeon 34000, Republic of Korea
- Hanyang University (KR)
- Konyang University (KR)
- Corresponding author
- Cho, Hyun-Jeong
- Ryu, Jin-Hyeob
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2026-01-07
- Volume
- 27
- Issue
- 2
- Pages
- 615
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC12840692
- OpenAlex
- W7118540561
- Semantic Scholar
- dfe84b28d6e0e0ae955fcb89edbd7494a40e3a6d
- Cited by
- 2
- References
- 70
- Citations by year
- 2026: 2
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Ministry of SMEs and Startups (RS-2023-00283779)
- Topics
- Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics › Neurogenetic and Muscular Disorders Research
- Keywords
- amyotrophic lateral sclerosis, miR-485-3p, PGC-1α, antisense oligonucleotides, nanoparticle drug delivery, microglia, neuroinflammation, mitochondrial function, neurofilament light chain, neuromuscular junction, motor neuron degeneration, ALS therapy
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Superoxide Dismutase-1, Amyotrophic Lateral Sclerosis, Animals, Disease Models, Animal, Humans, Mice, Transgenic, Spinal Cord, Signal Transduction, Oligonucleotides, Antisense, MicroRNAs, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
